According to a recent LinkedIn post from AAVantgarde Bio, the company’s chief medical officer, Jayashree Sahni, participated in the Macular Society’s Clinical Trial Delivery Accelerator summit in the U.K. The post indicates she presented on AAVantgarde Bio’s recent clinical developments alongside representatives from Boehringer Ingelheim, Complement Therapeutics, IQVIA, and several academic centers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that the summit focused on establishing new pathways for U.K.-based ophthalmology clinical trials that could accelerate the progression of therapeutics to market. For investors, this suggests AAVantgarde Bio is actively engaged in shaping clinical trial infrastructure in inherited retinal diseases and Stargardt disease, which may improve its future trial efficiency and reinforce its positioning within the ophthalmology and gene-therapy ecosystem.